Valerion Unveils Groundbreaking Innovations at CES 2025, Pushing the Boundaries of Home Projection Technology
LAS VEGAS, Jan. 4, 2025 /PRNewswire/ -- Valerion, the disruptor in the home theater industry, is redefining the future of entertainment by bringing Hollywood standard directly into homes. With the unprecedented success of its VisionMaster Series, Valerion became the most funded project of 2024 on Kickstarter, raising over $10.7 million—making it the highest-funded projector in crowdfunding history. At CES 2025, Valerion will debut the flagship VisionMaster MAX demonstration and the groundbreaking External Lens Concept and showcase the full VisionMaster Series, setting a new benchmark for home entertainment technology.
Valerion VisionMaster MAX Global Debut at CES 2025
At CES 2025, Valerion will globally debut the VisionMaster MAX, a cinematic-grade home theater projector that has generated immense anticipation since its crowdfunding launch. As the flagship model of the VisionMaster series, it brings groundbreaking advancements in home entertainment, setting a new standard for cinematic-quality projection. The VisionMaster MAX is equipped with the professional-grade OpticFlex Lens System, offering exceptional flexibility with optical zoom, vertical lens shift, and dynamic iris, allowing for a fully customizable and immersive viewing experience. With 3000 ISO lumens, a 15,000:1 contrast ratio powered by EBL technology, and 110% Rec. 2020 color gamut, the MAX delivers stunning image quality and vivid color accuracy. Its ability to project up to 300'' ensures an expansive, theater-like experience at home. Enhanced by Dolby Vision, IMAX Enhanced, Filmmaker Mode, and Active 3D, the VisionMaster MAX guarantees an unparalleled visual experience for all types of content. Additionally, the MAX introduces an innovative external lens that expands the throw ratio, offering even greater versatility and further elevating the home entertainment experience.
Next-Generation Home Theater and Gaming Solutions
At CES 2025, Valerion will showcase a new standard in home entertainment with its massive 220'' 4K Home Theater System Solution. Powered by industry-leading standards such as IMAX Enhanced, Dolby Vision, a 15,000:1 contrast ratio, and Dynamic Tone Mapping (DTM), it delivers cinematic-grade visuals, immersive stunning 3D effects and flawless precision on an ultra-large screen. The gaming demonstration showcases ultra-responsive visuals with a groundbreaking 4ms latency, enabling precise control and fluid performance for an engaging and competitive gaming experience. The Backyard Theater solution combines portability with exceptional image quality, delivering bright, vivid visuals that let you enjoy a movie night under the stars, all from the comfort of your home. Valerion also brings projection to everyday spaces, transforming bedrooms and living rooms into cozy and luxurious entertainment hubs, ensuring the magic of Hollywood is never far away.
CES 2025 Event Details:
- Date: January 7-10, 2025
- Location: Las Vegas Convention Center (LVCC), Central Hall, Booth 21614.
Availability
After its record-breaking Kickstarter campaign, the VisionMaster Series is now available for global pre-order on Valerion's website, with deliveries starting February 2025. Visit the website to secure your order, explore this revolutionary projection technology, and enjoy an exclusive $500 OFF (exclude VisionMaster MAX model).
About Valerion:
Valerion specializes in home cinema projectors, delivering the ultimate cinematic experience with advanced RGB laser technology and precision-engineered lens systems. The VisionMaster series, our flagship line, sets new benchmarks for home theater innovation. Committed to excellence in home entertainment, we harness cutting-edge technology to provide an unmatched, immersive viewing experience.
Media Contact
Email: marketing@valerion.com
Website: www.valerion.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Valerion Unveils VisionMaster Max at CES 2025: A Game-Changer in Projector Industry
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
